Zacks small cap research.

Research and development expenses in the 3rd quarter of 2023 were $469,000 which was similar to R&D expenses in the 3rd quarter of 2022 of $468,000. R&D expenses include the use of third-party contractors for further R&D activities, the performance of usability studies for the PressureSafe device, and non-cash expenses relating to stock-based ...Alpha-1062 Extended-Release Bioequivalence Study Topline Results. Results from the second bioequivalence study were shared with investors a few weeks ago on August 22, 2022. The data demonstrated pharmacokinetic equivalence between 5 mg of Alpha-1062 delayed release tablets and 8 mg galantamine hydrobromide extended …16 Feb 2022 ... With Sharesight, investors can get Zacks Investment Research news directly in their portfolio for US stocks. ... Small Caps and ausbiz. Sharesight ...In mid-July, Lantern announced the start of the Harmonic trial that will evaluate LP-300 in never smokers with non-small cell lung cancer (NSCLC). 90 subjects are expected to enroll in the Phase II study at 15 – 20 sites around the United States with enrollment expected to last from 12 to 16 months. It will target never smokers with lung ...

Management reiterated its outlook of revenues between $14.0 and $15.0 million in 2023. Operational and scientific highlights for 2Q:23 and to date include: Import license granted for Indonesia, Malaysia and South Africa – April 2023. Teijin license fee remitted – April 2023. Three patent issue notifications received – April 2023.1. Source: Created by Zacks Small Cap Research Analysts. By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT BALANCE Interim Results On June 2, 2021, Protalix and development partner, Chiesi Global Rare Diseases, provided an update regarding clinical development of Protalix’ candidate pegunigalsidase alfa (PRX …

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

Zacks Small Cap Research. TSEM: Increased Capacity is Yielding Record Sales at Tower Semiconductor. Read full article. Zacks Small Cap Research. May 13, 2021 at 5:32 AM ...May 22, 2023 · By Thomas Kerr, CFA. NASDAQ:GRIL. READ THE FULL GRIL RESEARCH REPORT. Muscle Maker Inc. (NASDAQ:GRIL), has evolved into a diversified, global food company with two distinct business units: 1) Sadot LLC – an international agricultural commodity supply-chain organization and 2) MMI Restaurant Group – an operator and franchisor of 50+ healthier-for-you fast casual concepts plus a subscription ... Jul 31, 2023 · Similar to other regions, penetration into the near 22,000 low risk SCCHN cases is expected to start at 3% and rise to 30% by year six then market share stabilization and declines in 2033 and 2034. The final geography that we include in our DCF model is the UK. According to Cancer Research UK, there are about 12,400 head and neck cancers. Put on Your Rally Cap, as We Turn the Last Two Inside-Out Do you get the sense that folks were more bullish after last Wednesday's rally than they were after Monday's rally? That's the sense I get. I suppose that is because last week's rug ...

In 4Q22, Novonix Anode Materials was selected to enter negotiations to receive US$150 million in grant funding from the Department of Energy (DOE) to expand its domestic synthetic graphite anode materials production, which we view as a positive. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports …

Nov 22, 2023 · Research and development expenses in the 3rd quarter of 2023 were $469,000 which was similar to R&D expenses in the 3rd quarter of 2022 of $468,000. R&D expenses include the use of third-party contractors for further R&D activities, the performance of usability studies for the PressureSafe device, and non-cash expenses relating to stock-based ...

Image: Bigstock 5 Top-Ranked Small-Cap Stocks to Boost Your Portfolio in 2021 (revised) Nalak Das December 14, 2020 TITN HZO STRT Better trading starts …In mid-July, Lantern announced the start of the Harmonic trial that will evaluate LP-300 in never smokers with non-small cell lung cancer (NSCLC). 90 subjects are expected to enroll in the Phase II study at 15 – 20 sites around the United States with enrollment expected to last from 12 to 16 months. It will target never smokers with lung ...SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, ...John Vandermosten, CFA is currently a Senior Analyst for Zacks Investment Research where he covers a portfolio of small cap biotechnology names. His background includes 19 years of experience in a variety of investment management and research roles across all market cap ranges and throughout the capital structure. John is a frequent moderator ...SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …The following disclosures relate to relationships between Zacks Small-Cap Research ( Zacks SCR ), a division of Zacks Investment Research ( ZIR ), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe. ANALYST DISCLOSURES. Zacks SCR Analysts hereby certify that the view expressed in this research report or article ...

David Bautz, PhD, Senior Analyst for Zacks Small-Cap Research, with 9 years of direct experience in the securities and investment industry. David’s research articles have been posted extensively on Yahoo Finance News and throughout life sciences social media circles. Prior to joining Zacks in 2014, David was an NRSA postdoctoral fellow ...By Lisa Thompson OTC:NEXCF CSE:TGGL READ THE FULL NEXCF RESEARCH REPORT Nextech (OTC:NEXCF) reported Q2 revenues of $1.4 million, up $100,000 sequentially from Q1 and 153% from Q2 2022. The company had preannounced this number on August 1st. Investors are still awaiting news that Nextech’s 3D modeling …On May 9, 2023, Lantern Pharma, Inc. (NASDAQ:LTRN) announced 2022 financial and operational results, filed its Form 10-Q with the SEC and hosted a video webcast to review accomplishments. In the last six weeks, Lantern has dosed its first patient in the Phase II Harmonic study, announced receipt of a patent allowance by the USPTO …Zacks Investment Research Page 4 scr.zacks.com The company has already presold the bulk of its 2023 capacity (and likely a significant portion of 2024 capacity) to customers and continues to announce customer wins with industry leaders in the energy storage market.Zacks Rank N/A BIOR: Precision Release – Surgical Strike on the GI Tract Zacks Small-Cap Research Joh Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

Zacks Small-Cap Research Sponsored – Impartial – Comprehensive November 8, 2023 John D. Vandermosten, CFA scr.zacks.com 312-265-9588 / [email protected] …

Zacks Small-Cap Research Sponsored – Impartial - Comprehensive November 16, 2023 David Bautz, PhD 312-265-9471 [email protected] Sponsored – Impartial - …Wheel center caps are an important component of your vehicle’s overall aesthetic appeal. Not only do they enhance the appearance of your wheels, but they also protect the hub and lug nuts from dirt, debris, and damage.Alpha-1062 Extended-Release Bioequivalence Study Topline Results. Results from the second bioequivalence study were shared with investors a few weeks ago on August 22, 2022. The data demonstrated pharmacokinetic equivalence between 5 mg of Alpha-1062 delayed release tablets and 8 mg galantamine hydrobromide extended …Zacks Small Cap Research Coverage Universe. For access to our most recent reports, please click on the links below. To join our paid real time email service please enter your email address and select the companies you would like to follow. An email will be sent to you for payment and setup instructions. Special Situations / Steven Ralston, CFA.When it comes to maintaining and enhancing the appearance of your vehicle, even the smallest details matter. One such detail that often goes overlooked is the wheel center caps. These small, circular covers not only add a touch of style to ...Zacks Rank N/A Correlation Study Complete Zacks Small-Cap Research John D. Vandermosten, CFA Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 September 23, 2022 312-265-9588 / [email protected] Revenue (In millions of USD) Q1 Q2 Q3 Q4 YearYes, absolutely. Zacks is worth it. Given that the stocks they rate as a #1 Strong Buy have beat the SP500 by 13.9% on average for the last 34 years, their system works. And the fact that the stocks they rate as a #5 Strong Sell have underperformed the market by 8.4% all but proves their system.Research Reports. Companies by Analyst. Steven Ralston, CFA; David Bautz, PhD; Ann Heffron, CFA, CPA; Thomas Kerr, CFA; Brian Lantier, CFA; M. Marin; Brad Sorensen, …Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted results from its Ongoing Research of Cytisinicline for Addiction, Vaping (ORCA-V1) trial and hosted a conference call for investors on April 20, 2023. The Phase II ORCA-V1 trial was conducted to measure the safety and effectiveness of 3 mg of cytisinicline dosed three times daily for 12 weeks ...The estimate for 2022 is up $1.56 (44.8%) in the last 90 days. The 2023 estimate is up $1.34 (33.6%) during the same time period. The earnings beat in the last quarter of 91.5% is greater than the ...

Nov 13, 2023 · By Brad Sorensen, CFA NASDAQ:ONVO READ THE FULL ONVO RESEARCH REPORT Organovo (NASDAQ:ONVO) reported its fiscal 2Q earnings and results were roughly inline with our expectations and illustrate to us that the company continues to progress toward bringing important products to market. Specifically, the company reported: • Earnings of -$0.46 per share, in line with estimates as expenses remained

By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update AdCom Granted for NurOwn® On March 27, 2023, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced that the U.S. Food and Drug Administration (FDA) has granted an Advisory Committee (AdCom) meeting to discuss …

“Yes! Success!” “Yes! Success!” It wasn’t quite “Mr. Watson. Come Here. I need you.” but it could prove to be just as revolutionary: Researchers at the University of Washington have completed the first experiment demonstrating human brain-t...Zacks Small-Cap Research Sponsored – Impartial – Comprehensive October 9, 2023 John D. Vandermosten, CFA 312-265-9588 / [email protected] scr.zacks.com 10 S. …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Zacks Small-Cap Research Lisa R. Thompson 312-265-9154 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 January 18, 2022 Preannounces Q4 Revenues of $8.8 Million up 275% Based on a blended enterprise value to sales multiple of its peers of 5.85 times, we believeExpense Ratio 1.390%. Distribution Fee Level High. Share Class Type No Load. Category Small Blend. Investment Style Small Blend. Min. Initial Investment 2,500. Status Open. TTM Yield 0.47% ...Nov 27, 2023 · On November 19, 2023, MediciNova, Inc. (NASDAQ:MNOV) announced new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) were presented at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) ( Lauko et al., 2023 ). The Phase 2 clinical trial enrolled 62 GBM patients (36 newly diagnosed and 26 ... The details of 2Q 2023: • Revenue for the quarter came in at $1,480,388, which was more than double the revenue seen in the previous quarter of just over $625,000. • FRX posted a quarterly loss of $0.02 per share, slightly ahead of our estimates due largely to an improvement in the gross margin. • Gross margins improved to a gain of ...'Who needs breadth when we have Nvidia's beat?': We've been here before, and I can tell you it lasts longer than it should. Let's look at charts and indicators, past and present....NVDA We're in that part of the cycle wh...Oct 31, 2023 · Fund Description. The fund was incepted in May 2000 and is managed by Franklin Advisers. The objective of this fund is long-term capital growth. The fund invests at least 80% of its net assets in ...

Zacks Investment Research: A company, founded in 1977, dedicated to providing professional investors with the financial data and analysis needed to make …Jun 14, 2023 · Raises Gross Proceeds of $55 Million to Advance Lead Compound to Clinical Trials. On My 17, 2023, Satellos Biosciences Inc. (OTC:MSCLF) announced it closed an equity offering in which it raised gross proceeds of $55 million from the issuance of 110 million equity securities at $0.50 per common share or pre-funded warrant (70,297,220 common ... SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Instagram:https://instagram. dupixent pricesaor etfwhat's the value of a 1921 silver dollarbuybackboss review By Thomas Kerr, CFA NASDAQ:UXIN READ THE FULL UXIN RESEARCH REPORT On December 30th, Uxin (NASDAQ:UXIN) reported fiscal 2nd quarter operating and financial results for the three-month period ending September 30, 2022. Total revenues increased to $87 million which was a 1.2% increase from the fiscal 1st quarter and a … russell.2000largest stock movers Zacks Small-Cap Research Tom Kerr 312-265-9147 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 November 14, 2022 UPDATE: Siyata reported 2022 3rd quarter financial results which showed high revenue growth rates compared to the prior year period. Utilizing a DCF valuation process containingThe details of 2Q 2023: • Revenue for the quarter came in at $1,480,388, which was more than double the revenue seen in the previous quarter of just over $625,000. • FRX posted a quarterly loss of $0.02 per share, slightly ahead of our estimates due largely to an improvement in the gross margin. • Gross margins improved to a gain of ... best investment blogs We run some scenario analyses to evaluate the total cost of an entity acquiring Tenax. If an acquiror’s bid price was set at $1.00 per share, the estimated cost to acquire the company would be approximately $52 million. At $2.00 per share, the price increases to $131 million and at $3.00, $210 million. See exhibit below for details on the ...By Thomas Kerr, CFA NASDAQ:UXIN READ THE FULL UXIN RESEARCH REPORT On December 30th, Uxin (NASDAQ:UXIN) reported fiscal 2nd quarter operating and financial results for the three-month period ending September 30, 2022. Total revenues increased to $87 million which was a 1.2% increase from the fiscal 1st quarter and a 78.9% increase from the prior year period. Unit volume was 6,050 vehicles in theZacks now provides investment data, market data systems, proprietary quantitative models, analyst written research, investor relations,. SEC compliance and XBRL ...